Analyst Price Targets — NVCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 24, 2026 11:47 am | — | Wedbush | $20.00 | $19.99 | TheFly | Novocure price target raised to $20 from $18 at Wedbush |
| July 24, 2026 11:31 am | Emily Bodnar | H.C. Wainwright | $32.00 | $19.99 | StreetInsider | NovoCure Ltd. (NVCR) PT Lowered to $32 at H.C. Wainwright |
| July 23, 2026 4:54 pm | — | H.C. Wainwright | $52.00 | $19.87 | TheFly | Novocure price target raised to $52 from $46 at H.C. Wainwright |
| June 18, 2026 2:59 pm | Emily Bodnar | H.C. Wainwright | $46.00 | $14.57 | TheFly | Novocure price target lowered to $46 from $48 at H.C. Wainwright |
| February 12, 2026 11:04 am | — | H.C. Wainwright | $47.00 | $13.74 | TheFly | Novocure price target raised to $47 from $39 at H.C. Wainwright |
| January 13, 2026 11:03 am | — | H.C. Wainwright | $39.00 | $14.18 | TheFly | Novocure price target lowered to $39 from $42 at H.C. Wainwright |
| January 5, 2026 2:54 pm | — | Evercore ISI | $20.00 | $13.71 | TheFly | Novocure price target lowered to $20 from $22 at Evercore ISI |
| October 30, 2025 4:11 pm | — | H.C. Wainwright | $42.00 | $13.18 | TheFly | Novocure price target raised to $42 from $38 at H.C. Wainwright |
| July 24, 2025 8:09 pm | Larry Biegelsen | Wells Fargo | $14.50 | $12.54 | TheFly | Novocure downgraded to Equal Weight from Overweight at Wells Fargo |
| December 2, 2024 11:00 am | Vijay Kumar | Evercore ISI | $30.00 | $26.43 | StreetInsider | Evercore ISI Upgrades NovoCure Ltd. (NVCR) to Outperform 'into Panova readout on asymmetric risk/reward' |
Latest News for NVCR
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief Executive Officer, will take part in a fireside chat at 10:15 a.m. ET, as well as one-on-one meetings with investors. Morgan Stanley 24th Annual Global Healthcare Conference, September 14,…
Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to certain information systems in mid-August exposed internal records of more than 1,400 U.S. patients.
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NVCR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.